Technetium (99mTc) sulesomab explained

Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]

It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis[4] [5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.[7] [8] [9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.[10]

See also

Notes and References

  1. Web site: WHO Drug Information . 2009-10-25 . https://web.archive.org/web/20120219143028/http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list75.pdf . 2012-02-19 . dead .
  2. Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ . Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections . Medical Principles and Practice . 17 . 6 . 447–52 . 2008 . 18836272 . 10.1159/000151565 . free .
  3. Skehan SJ, White JF, Evans JW, Parry-Jones DR, Solanki CK, Ballinger JR, Chilvers ER, Peters AM . 6 . Mechanism of accumulation of 99mTc-sulesomab in inflammation . Journal of Nuclear Medicine . 44 . 1 . 11–8 . January 2003 . 12515870 . 2019-12-10 . https://web.archive.org/web/20191210192401/http://jnm.snmjournals.org/content/44/1/11 . 2019-12-10 . live .
  4. http://www.emea.europa.eu/humandocs/PDFs/EPAR/leukoscan/H-111-PI-en.pdf EMEA: Summary of product characteristics (LeukoScan)
  5. Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H . Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations . The Quarterly Journal of Nuclear Medicine and Molecular Imaging . 60 . 4 . 413–23 . December 2016 . 25325395 .
  6. Vicente AG, Almoguera M, Alonso JC, Heffernan AJ, Gomez A, Contreras PI, Martin-Comin J . Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2) . Clinical Nuclear Medicine . 29 . 12 . 781–5 . December 2004 . 15545877 . 10.1097/00003072-200412000-00001 . 46580717 .
  7. Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ . Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections . Medical Principles and Practice . 17 . 6 . 447–52 . 2008 . 18836272 . 10.1159/000151565 . free .
  8. Galletti F, Cammaroto G, Galletti B, Quartuccio N, Di Mauro F, Baldari S . Technetium-99m (99mTc)-labelled sulesomab in the management of malignant external otitis: is there any role? . European Archives of Oto-Rhino-Laryngology . 272 . 6 . 1377–82 . June 2015 . 24534898 . 10.1007/s00405-014-2938-1 . 25194736 .
  9. Iyengar KP, Vinjamuri S . Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections . Nuclear Medicine Communications . 26 . 6 . 489–96 . June 2005 . 15891591 . 10.1097/00006231-200506000-00003 . 41915486 .
  10. Web site: Products. Immunomedics. en-US. 2019-12-10. https://web.archive.org/web/20191210192350/https://www.immunomedics.com/our-science/products/. 2019-12-10. live.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Technetium (99mTc) sulesomab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.